Influence of Men’s Personality and Social Support on Treatment Decision-Making for Localized Prostate Cancer
Table 1
Differences in demographic, clinical, and personality characteristics by race and treatment choice.
Variable
Total
By race
By treatment choice
(%)
White (%)
Black (%)
-
WW/AS (%)
Radiation (%)
Surgery (%)
-
Age
Mean (SD)
61.0 (7.3)
61.8 (6.5)
60.1 (8.2)
0.14
64.6 (7.4)
63.0 (6.9)
59.4 (7.1)
<0.01
Less than 65
102 (63.8)
55 (61.8)
47 (66.2)
0.68
8 (50.0)
28 (56.0)
66 (70.2)
0.12
65 and greater
58 (36.3)
34 (38.2)
24 (33.8)
8 (50.0)
22 (44.0)
28 (29.8)
# of comorbidities
0
34 (21.3)
22 (24.7)
12 (16.9)
0.42
3 (18.8)
4 (8.0)
27 (28.7)
0.02
1
60 (37.5)
31 (34.8)
29 (40.8)
4 (25.0)
21 (42.0)
35 (37.2)
2
38 (23.8)
23 (25.8)
15 (21.1)
6 (37.5)
11 (22.0)
21 (22.3)
≥3
28 (17.5)
13 (14.6)
15 (21.1)
3 (18.8)
14 (28.0)
11 (11.7)
PSA level
≤4
66 (42.0)
39 (44.3)
27 (39.1)
0.59
4 (26.7)
23 (46.0)
39 (42.4)
0.61
5–9
70 (44.6)
40 (45.5)
30 (43.5)
7 (46.7)
21 (42.0)
42 (45.7)
10–19
8 (5.1)
3 (3.4)
5 (7.2)
2 (13.3)
2 (4.0)
4 (4.3)
≥20
13 (8.3)
6 (6.8)
7 (10.1)
2 (13.3)
4 (8.0)
7 (7.6)
Gleason score
≤6
80 (50.0)
50 (56.2)
30 (42.3)
0.16
8 (50.0)
30 (60.0)
42 (44.7)
0.04
7
65 (40.6)
33 (37.1)
32 (45.1)
4 (25.0)
15 (30.0)
46 (48.9)
8–10
15 (9.4)
6 (6.7)
9 (12.7)
4 (25.0)
5 (10.0)
6 (6.4)
Tumor risk
Low
28 (18.3)
17 (19.5)
11 (16.7)
0.79
5 (33.3)
19 (42.2)
4 (4.3)
<0.01
Intermediate
44 (28.8)
26 (29.9)
18 (27.3)
8 (53.3)
15 (33.3)
21 (22.6)
High
81 (52.9)
44 (50.6)
37 (56.1)
2 (13.3)
11 (24.4)
68 (73.1)
Treatment started/received by survey
Yes
103 (64.4)
63 (70.8)
40 (56.3)
0.08
5 (31.3)
35 (70.0)
63 (67.0)
0.02
No
57 (35.6)
26 (29.2)
31 (43.7)
11 (68.8)
15 (30.0)
31 (33.0)
Education
≤High school
101 (63.5)
47 (53.4)
54 (76.1)
<0.01
11 (68.8)
35 (70.0)
55 (59.1)
0.40
>High school
58 (36.5)
41 (46.6)
17 (23.9)
5 (31.3)
15 (30.0)
38 (40.9)
Married/partnered
Yes
127 (80.4)
79 (89.8)
48 (68.6)
<0.01
12 (75.0)
40 (81.6)
75 (80.6)
0.84
No
31 (19.6)
9 (10.2)
22 (31.4)
4 (25.0)
9 (18.4)
18 (19.4)
Consulted family
Yes
85 (53.5)
38 (43.2)
47 (66.2)
<0.01
6 (37.5)
28 (56.0)
51 (54.8)
0.42
No
74 (46.5)
50 (56.8)
24 (33.8)
10 (62.5)
22 (44.0)
42 (45.2)
Consulted friends
Yes
85 (53.5)
48 (54.5)
37 (52.1)
0.88
3 (18.8)
31 (62.0)
42 (45.2)
<0.01
No
74 (46.5)
40 (45.5)
34 (47.9)
13 (81.3)
19 (38.0)
51 (54.8)
Consulted spouse/partner
Yes
120 (76.9)
65 (74.7)
55 (79.7)
0.59
8 (57.1)
38 (77.6)
74 (79.6)
0.20
No
36 (23.1)
22 (25.3)
14 (20.3)
6 (42.9)
11 (22.4)
19 (20.4)
Physician seen
Urologist only
15 (9.2)
11 (13.3)
4 (6.8)
0.47
3 (18.8)
2 (4.3)
10 (12.3)
<0.01
Urologist/PCP only
59 (41.5)
33 (37.3)
26 (44.1)
7 (43.8)
5 (10.6)
47 (58.0)
Rad. onc. ± urologist/PCP
70 (49.3)
41 (49.4)
29 (49.2)
6 (37.5)
40 (85.1)
24 (29.6)
Mean (SD)
4.0 (0.8)
3.9 (0.7)
4.0 (0.9)
0.44
4.1 (0.6)
4.2 (0.5)
3.9 (0.9)
0.09
Mean (SD)
2.0 (0.8)
1.9 (0.7)
2.0 (0.9)
0.42
1.8 (0.7)
1.9 (0.7)
2.0 (0.8)
0.24
Mean (SD)
3.5 (1.1)
3.1 (1.1)
3.9 (1.1)
<0.01
3.3 (1.2)
3.6 (1.1)
3.4 (1.2)
0.97
values were calculated using chi-square test or Fisher’s exact test for dichotomous data and -tests or ANOVA for continuous outcomes. risk level categorized using the American Urological Association endorsed D’Amico criteria: low indicates PSA level < 10, Gleason score ≤ 6, and clinical stage T1-2a; intermediate indicates PSA of 10–20, Gleason score of 7, and clinical stage T2b; high indicates PSA > 20, Gleason score ≥ 8, and clinical stage T2c-3a. on a scale of 1 to 5: 1, not at all true, and 5, completely true.
